Hemoglobin‐platelet index as a prognostic factor in patients with peripheral T‐cell lymphoma

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive lymphomas with poor prognosis. The International Prognostic Index (IPI) and the for PTCL-unspecified (PIT) used to predict prognosis PTCL. hemoglobin-platelet index (HPI), based on anemia thrombocytopenia status, associated diffuse large B-cell lymphoma. However, its significance in terms predicting PTCL has not been fully investigated. We herein retrospectively analyzed 100 patients newly diagnosed our department. At median follow-up 3.2 years, progression-free survival (PFS) overall (OS) was 0.72 (95% confidence interval [CI]: 0.56–1.2) years 2.0 CI: 1.5–4.7) respectively. Multivariate analysis revealed that elevated lactic dehydrogenase (LDH) hypoalbuminemia were independent adverse variables PFS. HPI showed significant predictive value both PFS OS. As new prognostic model comprising HPI, LDH, albumin, LA-HPI allowed stratification into four distinct risk subgroups: low (zero factors), low-intermediate (one high-intermediate (two or three high (four factors). OS differed significantly among by score. demonstrated better performance compared IPI, PIT, HPI. Our data utility LA-HPI, incorporating readily obtainable parameters, exhibited superior traditional indices.